These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11904735)

  • 1. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma.
    Kremens B; Hero B; Esser J; Weinel P; Filger-Brillinger J; Fleischhack G; Graf N; Grüttner HP; Niemeyer C; Schulz A; Wickmann L; Berthold F
    Cancer Immunol Immunother; 2002 Apr; 51(2):107-10. PubMed ID: 11904735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.
    Terme M; Dorvillius M; Cochonneau D; Chaumette T; Xiao W; Diccianni MB; Barbet J; Yu AL; Paris F; Sorkin LS; Birklé S
    PLoS One; 2014; 9(2):e87210. PubMed ID: 24520328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD
    Mueller I; Ehlert K; Endres S; Pill L; Siebert N; Kietz S; Brock P; Garaventa A; Valteau-Couanet D; Janzek E; Hosten N; Zinke A; Barthlen W; Varol E; Loibner H; Ladenstein R; Lode HN
    MAbs; 2018 Jan; 10(1):55-61. PubMed ID: 29120699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.
    Yu AL; Uttenreuther-Fischer MM; Huang CS; Tsui CC; Gillies SD; Reisfeld RA; Kung FH
    J Clin Oncol; 1998 Jun; 16(6):2169-80. PubMed ID: 9626218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study.
    Ozkaynak MF; Sondel PM; Krailo MD; Gan J; Javorsky B; Reisfeld RA; Matthay KK; Reaman GH; Seeger RC
    J Clin Oncol; 2000 Dec; 18(24):4077-85. PubMed ID: 11118469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
    Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
    Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD
    Ceylan K; Jahns LJ; Lode BN; Ehlert K; Kietz S; Troschke-Meurer S; Siebert N; Lode HN
    Pediatr Blood Cancer; 2018 Jun; 65(6):e26967. PubMed ID: 29350486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
    Siebert N; Eger C; Seidel D; Jüttner M; Lode HN
    J Immunol Methods; 2014 May; 407():108-15. PubMed ID: 24727144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexmedetomidine and hydromorphone: a novel pain management strategy for the oncology ward setting during anti-GD2 immunotherapy for high-risk neuroblastoma in children.
    Görges M; West N; Deyell R; Winton P; Cheung W; Lauder G
    Pediatr Blood Cancer; 2015 Jan; 62(1):29-34. PubMed ID: 25263424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
    Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN
    J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14.18K322A.
    Tse BC; Navid F; Billups CA; O'Donnell T; Hoehn ME
    J AAPOS; 2015 Apr; 19(2):112-5. PubMed ID: 25818285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma.
    Handgretinger R; Anderson K; Lang P; Dopfer R; Klingebiel T; Schrappe M; Reuland P; Gillies SD; Reisfeld RA; Neithammer D
    Eur J Cancer; 1995; 31A(2):261-7. PubMed ID: 7718335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients.
    Uttenreuther-Fischer MM; Huang CS; Yu AL
    Cancer Immunol Immunother; 1995 Dec; 41(6):331-8. PubMed ID: 8635190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
    Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN
    Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: a possible vaccine against tumors of neuroectodermal origin?
    Uttenreuther-Fischer MM; Krüger JA; Fischer P
    J Immunol; 2006 Jun; 176(12):7775-86. PubMed ID: 16751426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
    Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
    Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.
    Desai AV; Fox E; Smith LM; Lim AP; Maris JM; Balis FM
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1047-55. PubMed ID: 25212536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.
    Anghelescu DL; Goldberg JL; Faughnan LG; Wu J; Mao S; Furman WL; Santana VM; Navid F
    Pediatr Blood Cancer; 2015 Feb; 62(2):224-228. PubMed ID: 25382742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
    Yu AL; Gilman AL; Ozkaynak MF; London WB; Kreissman SG; Chen HX; Smith M; Anderson B; Villablanca JG; Matthay KK; Shimada H; Grupp SA; Seeger R; Reynolds CP; Buxton A; Reisfeld RA; Gillies SD; Cohn SL; Maris JM; Sondel PM;
    N Engl J Med; 2010 Sep; 363(14):1324-34. PubMed ID: 20879881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.